Cited by 2,003Bone health and osteoporosis researchBone health and treatmentsHip and Femur Fractures

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Open access

Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven·2007·New England Journal of Medicine

DOI 10.1056/nejmoa074941PMC PMC2324066

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa074941

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Vitamin D Deficiency
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 2

Davidson CW, 2001, N Z Med J, 114, 329
2003, World Health Organ Tech Rep Ser, 921, 1

Sorted by citations

Items 201–300 of 1,000

Osteoporosis as a Risk Factor for Distal Radial Fractures
Øyen, J., Brudvik, C. E., Gjesdal, C. G., Tell, G. S., Lie, S. A., & Hove, L. M. (2011) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.00303 · Cited by 102
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Russell, R. G. G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s8054 · Cited by 102
Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study
Cooper, M. S., Palmer, A. J., & Seibel, M. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1802-z · Cited by 100
Clinical risk factors, bone density and fall history in the prediction of incident fracture among men and women
Edwards, M. H., Jameson, K., Denison, H. J., Harvey, N. C., Sayer, A. A., Dennison, E. M., & Cooper, C. C. (2012) · Bone · doi:10.1016/j.bone.2012.11.006 · Cited by 99
Atypical Subtrochanteric Femoral Fractures in Patients with Skeletal Malignant Involvement Treated with Intravenous Bisphosphonates
Puhaindran, M. E., Farooki, A., Steensma, M. R., Hameed, M., Healey, J. H., & Boland, P. J. (2011) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.01199 · Cited by 100
Musculoskeletal Frailty: A Geriatric Syndrome at the Core of Fracture Occurrence in Older Age
Gielen, E., Verschueren, S., O’Neill, T. W., Pye, S. R., O’Connell, M. D. L., Lee, D. M., Ravindrarajah, R., Claessens, F., Laurent, M. R., Milisen, K., et al. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9622-5 · Cited by 101
Self-citation
Osteoporosis Disease Management: What Every Orthopaedic Surgeon Should Know
Dell, R. M., Greene, D. F., Anderson, D., & Williams, K. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00521 · Cited by 98
The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis
Byun, J.-H., Jang, S., Lee, S., Park, S., Yoon, H. K., Yoon, B., & Ha, Y. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.37 · Cited by 98
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates
Cummings, S. R., Lui, L., Eastell, R., & Allen, I. E. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2779 · Cited by 99
Safety of Bisphosphonates in the Treatment of Osteoporosis
Recker, R. R., Lewiecki, E. M., Miller, P. D., & Reiffel, J. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.004 · Cited by 98
Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture
Bawa, H. S., Weick, J. W., & Dirschl, D. R. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.01275 · Cited by 97
Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis
Dhillon, S. (2016) · Drugs · doi:10.1007/s40265-016-0662-4 · Cited by 96
Osteoporosis
Ye, C., Ebeling, P. R., & Kline, G. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01385-6 · Cited by 99
Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties
Ma, S., Goh, E. L., Jin, A., Bhattacharya, R., Boughton, O. R., Patel, B., Karunaratne, A., Vo, N. T., Atwood, R., Cobb, J. P., et al. (2017) · Scientific Reports · doi:10.1038/srep43399 · Cited by 94
Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture
Sing, C., Wong, A. Y. S., Kiel, D. P., Cheung, E. Y. N., Lam, J. K. Y., Cheung, T. T., Chan, E. W., Kung, A. W. C., Wong, I. C. K., & Cheung, C. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3448 · Cited by 94
The Role of Comorbidity in Mortality After Hip Fracture: A Nationwide Norwegian Study of 38,126 Women With Hip Fracture Matched to a General-Population Comparison Cohort
Lunde, A., Tell, G. S., Pedersen, A. B., Scheike, T., Apalset, E. M., Ehrenstein, V., & Sørensen, H. T. (2018) · American Journal of Epidemiology · doi:10.1093/aje/kwy251 · Cited by 98
Atrial fibrillation and bisphosphonate therapy
Pazianas, M., Compston, J. E., & Huang, C. L.-H. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091201 · Cited by 94
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Bastin, S., & Gamble, G. D. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3860 · Cited by 93
Management of osteoporosis of the oldest old
Rizzoli, R., Branco, J., Brandi, M. L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C. C., Díez‐Pérez, A., Duder, J., Fielding, R. A., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2755-9 · Cited by 94
Self-citation
Approach to the patient with secondary osteoporosis
Hofbauer, L. C., Hamann, C., & Ebeling, P. R. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0015 · Cited by 95
The prescribing cascade
Kalisch, L. M., Caughey, G. E., Roughead, E. E., & Gilbert, A. L. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.084 · Cited by 93
All-cause mortality risk in aged femoral intertrochanteric fracture patients
Li, X., Zhang, P., Zhu, S., Yang, M., Wu, X., & Jiang, X. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02874-9 · Cited by 95
Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: A prospective 5-year study
Cameron, I. D., Chen, J. S., MARCH, L. M., Simpson, J. M., Cumming, R. G., Seibel, M. J., & Sambrook, P. N. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091029 · Cited by 92
Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis?
Lee, Y., Ha, Y., Cho, Y. J., Suh, K. T., Kim, S., Won, Y., Min, B.-W., Yoon, T. R., Kim, H. J., & Koo, K. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.01157 · Cited by 92
Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective
Boonen, S., Dejaeger, E. W., Vanderschueren, D., Venken, K., Bogaerts, A., Verschueren, S., & Milisen, K. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.002 · Cited by 98
Self-citation
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons
Kim, K. M., Rhee, Y., Kwon, Y., Kwon, T., Lee, J. K., & Kim, D. (2015) · Journal of Bone Metabolism · doi:10.11005/jbm.2015.22.4.151 · Cited by 91
Drug-Induced Atrial Fibrillation
Kaakeh, Y., Overholser, B. R., Lopshire, J. C., & Tisdale, J. E. (2012) · Drugs · doi:10.2165/11633140-000000000-00000 · Cited by 90
EAA clinical guideline on management of bone health in the andrological outpatient clinic
Rochira, V., Antonio, L., & Vanderschueren, D. (2018) · Andrology · doi:10.1111/andr.12470 · Cited by 90
Building healthy bones throughout life: an evidence‐informed strategy to prevent osteoporosis in Australia
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2013.tb04225.x · Cited by 89
Progressively increasing fracture risk with advancing age after initial incident fragility fracture: The Tromsø Study
Ahmed, L. A., Bjørnerem, Å., Bliuc, D., Joakimsen, R. M., Jørgensen, L., Meyer, H. E., Nguyen, N. D., Nguyen, T. V., Omsland, T. K., Störmer, J., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1952 · Cited by 88
Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip Fracture
Miki, R. A., Oetgen, M. E., Kirk, J., Insogna, K. L., & Lindskog, D. M. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01246 · Cited by 88
How menopause affects oral health, and what we can do about it
Buencamino, M. C. A., Palomo, L., & Thacker, H. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.08095 · Cited by 88
Zoledronic Acid Treatment in Children with Osteogenesis Imperfecta
Vuorimies, I., Toiviainen‐Salo, S., Hero, M. T., & Mäkitie, O. (2011) · Hormone Research in Paediatrics · doi:10.1159/000323368 · Cited by 87
Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients’ and Practitioners’ Views
Alami, S., Hervouet, L., Poiraudeau, S., Briot, K., & Roux, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158365 · Cited by 91
Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures
Desai, R. J., Mahesri, M., Abdia, Y., Barberio, J., Tong, A., Zhang, D., Mavros, P., Kim, S. C., & Franklin, J. M. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0826 · Cited by 85
Osteoporosis in men
Gielen, E., Vanderschueren, D., Callewaert, F., & Boonen, S. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.08.012 · Cited by 85
Self-citation
Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010
Klop, C., Gibson-Smith, D., Elders, P. J. M., Welsing, P. M. J., Leufkens, H. G. M., Harvey, N. C., Bijlsma, J. W. J., van Staa, T. P., & de Vries, F. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3098-x · Cited by 84
Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies
Caffarelli, C., Montagnani, A., Nuti, R., & Gonnelli, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s138002 · Cited by 84
Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses
Zhou, J., Ma, X., Wang, T., & Zhai, S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3654-z · Cited by 84
Osteoporosis Case Manager for Patients With Hip Fractures
Majumdar, S. R., Lier, D. A., Beaupré, L. A., Hanley, D. A., Maksymowych, W. P., Juby, A. G., Bell, N. R., & Morrish, D. W. (2009) · Archives of Internal Medicine · doi:10.1001/archinte.169.1.25 · Cited by 83
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
Body, J. J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1891-8 · Cited by 86
Self-citation
The relation between bisphosphonate use and non-union of fractures of the humerus in older adults
Solomon, D. H., Hochberg, M. C., Mogun, H., & Schneeweiß, S. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0759-z · Cited by 83
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
Kang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2213-5 · Cited by 82
Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
Bock, O. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2134 · Cited by 82
Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Pereira, R. M. R., de Carvalho, J. F., de Paula, A. P., Zerbini, C. A. F., Domiciano, D. S., Gonçalves, H., Danowski, J. S., Neto, J. F. M., de Mendonça, L. M. C., Bezerra, M. C., et al. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000400009 · Cited by 80
Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?
Xu, X., Gou, W.-L., Wang, Y., Wang, Y., Guo, Q., Lu, Q., Lu, S., & Peng, J. C. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-303 · Cited by 79
Drugs, medications and periodontal disease
Heasman, P. A., & Hughes, F. J. (2014) · BDJ · doi:10.1038/sj.bdj.2014.905 · Cited by 79
Management of osteoporosis in the elderly
Rizzoli, R., Bruyère, O., Cannata-Andía, J. B., Devogelaer, J. P., Lyritis, G. P., Ringe, J. D., Vellas, B. J., & Reginster, J.-Y. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903169262 · Cited by 79
A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D
Henriksen, K., Byrjalsen, I., Andersen, J. R., Bihlet, A. R., Russo, L. A., Alexandersen, P., Valter, I., Qvist, P., Lau, E., Riis, B. J., et al. (2016) · Bone · doi:10.1016/j.bone.2016.07.019 · Cited by 78
Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study
van Geel, T. A. C. M., Bliuc, D., Geusens, P., Dinant, G., Tran, T. S., van den Bergh, J. P., McLellan, A. R., & Eisman, J. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198006 · Cited by 78
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
Nakamura, T., Fukunaga, M., Nakano, T., Kishimoto, H., Ito, M., Hagino, H., Sone, T., Taguchi, A., Tanaka, S., Ohashi, M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3736-y · Cited by 78
Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis
Jacqueline R. Center (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0352-5 · Cited by 78
Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study
Roux, C., Thomas, T., Paccou, J., Bizouard, G., Crochard, A., Tóth, E., Lemaître, M., Maurel, F., Perrin, L., & Tubach, F. (2021) · JBMR Plus · doi:10.1002/jbm4.10507 · Cited by 77
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old
Fuggle, N. R., Laslop, A., Rizzoli, R., Al‐Daghri, N. M., Alokail, M. S., Bałkowiec-Iskra, E., Beaudart, C., Bruyère, O., Bemden, A. B., Burlet, N., et al. (2025) · Drugs · doi:10.1007/s40265-024-02138-w · Cited by 78
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials
Li, Y., Cai, H., & Zhang, Z. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2903-2 · Cited by 77
Bisphosphonate‐associated osteonecrosis of the jaw,with healing after teriparatide:a review of the literature and a case report
Narongroeknawin, P., Danila, M. I., Humphreys, L. G., Barasch, A., & Curtis, J. R. (2010) · Special Care in Dentistry · doi:10.1111/j.1754-4505.2009.00128.x · Cited by 77
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study
Pazianas, M., Abrahamsen, B., Eiken, P., Eastell, R., & Russell, R. G. G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1902-4 · Cited by 76
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 81
Treatment of post-menopausal osteoporosis: beyond bisphosphonates
Ishtiaq, S., Fogelman, I., & Hampson, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0152-z · Cited by 80
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg
Wark, J. D., Bensen, W., Recknor, C. P., Ryabitseva, O. F., Chiodo, J., Mesenbrink, P. G., & de Villiers, T. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1563-8 · Cited by 76
Self-citation
An overview on the treatment of postmenopausal osteoporosis
Maeda, S. S., & Lazaretti‐Castro, M. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003039 · Cited by 79
Denosumab in Osteoporosis and Oncology
Burkiewicz, J. S., Scarpace, S. L., & Bruce, S. P. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m102 · Cited by 77
Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis
Sanderson, J., James, M. M., Stevens, J., Goka, E., Wong, R., Campbell, F., Selby, P. L., Gittoes, N. J. L., & Davis, S. (2016) · Bone · doi:10.1016/j.bone.2016.05.013 · Cited by 77
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures
Davis, S., James, M. M., Sanderson, J., Stevens, J., Goka, E., Rawdin, A., Sadler, S., Wong, R., Campbell, F., Stevenson, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20780 · Cited by 76
Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study
Pasco, J. A., Mohebbi, M., Holloway‐Kew, K. L., Brennan-Olsen, S. L., Hyde, N. K., & Kotowicz, M. A. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12177 · Cited by 76
Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway
Støen, R., Nordsletten, L., Meyer, H. E., Frihagen, F., Falch, J. A., & Lofthus, C. M. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1888-3 · Cited by 75
Self-citation
Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
Ferrari, S., Reginster, J., Brandi, M. L., Kanis, J. А., Devogelaer, J., Kaufman, J., Féron, J.-M., Kurth, A., & Rizzoli, R. (2016) · Archives of Osteoporosis · doi:10.1007/s11657-016-0292-1 · Cited by 75
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age
Bolland, M. J., Nisa, Z., Mellar, A., Gasteiger, C., Pinel, V., Mihov, B., Bastin, S., Grey, A. B., Reid, I. R., Gamble, G. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2407031 · Cited by 74
The Orthogeriatrics Model of Care: Systematic Review of Predictors of Institutionalization and Mortality in Post-Hip Fracture Patients and Evidence for Interventions
Martínez-Reig, M., Ahmad, L., & Duque, G. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.07.011 · Cited by 74
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies
Mak, A., Cheung, M. W. ‐., Ho, R., Cheak, A. A.-C., & Lau, C. S. (2009) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-10-113 · Cited by 74
Advances in the management of osteoporosis
Hoong, C. W. S., Saul, D., Khosla, S., & Sfeir, J. G. (2025) · BMJ · doi:10.1136/bmj-2024-081250 · Cited by 77
Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial
Grey, A. B., Bolland, M. J., Wattie, D. J., Horne, A. M., Gamble, G. D., & Reid, I. R. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.103 · Cited by 73
Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions
Curtis, J. R., & Safford, M. M. (2012) · Drugs & Aging · doi:10.2165/11599620-000000000-00000 · Cited by 74
Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation
Bunch, T. J., Anderson, J. L., May, H. T., Muhlestein, J. B., Horne, B. D., Crandall, B. G., Weiss, J. P., LAPPE, D. L., Osborn, J. S., & Day, J. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.037 · Cited by 73
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation
Cianferotti, L., Bertoldo, F., Carini, M., Kanis, J. А., Lapini, A., Longo, N., Martorana, G. E., Mirone, V. G., Reginster, J., Rizzoli, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17980 · Cited by 74
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
Eastell, R., Vittinghoff, E., Lui, L., McCulloch, C. E., Pavo, I. J., Chines, A. A., Khosla, S., Cauley, J. A., Mitlak, B., Bauer, D. C., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4433 · Cited by 73
Consensus statement on diagnosis and clinical management of Klinefelter syndrome
Radicioni, A. F., Ferlin, A., Balercia, G., Pasquali, D., Vignozzi, L., Maggi, M., Foresta, C., & Lenzi, A. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03350351 · Cited by 72
Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?
Kim, T., Ha, Y.-C., Kang, B.-J., Lee, Y., & Koo, K.-H. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b7.29079 · Cited by 72
Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss
Berenson, J. R., Yellin, O., Boccia, R. V., Flam, M. S., Wong, S., Batuman, O., Moezi, M. M., Woytowitz, D., Duvivier, H. L., Nassir, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0666 · Cited by 72
Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review
Im, G., & Lee, S.-H. (2015) · Journal of Bone Metabolism · doi:10.11005/jbm.2015.22.4.183 · Cited by 72
Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study
Brozek, W., Reichardt, B., Zwerina, J., Dimai, H. P., Klaushofer, K., & Zwettler, E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3415-4 · Cited by 72
Osteoporosis and Fractures
Cheung, A. M., & Detsky, A. S. (2008) · JAMA · doi:10.1001/jama.299.12.1468 · Cited by 71
Diagnosis and management of osteoporosis in the older senior
Vondracek, S. F. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4965 · Cited by 70
T-Scores and Z-Scores
CAREY, J. J., & Delaney, M. F. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9064-4 · Cited by 71
Preadmission Bisphosphonate and Mortality in Critically Ill Patients
Lee, P., Ng, C. M. A., Slattery, A., Nair, P., & Eisman, J. A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3467 · Cited by 70
Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis
Hawley, S. J., Leal, J., Delmestri, A., Prieto‐Alhambra, D., Arden, N., Cooper, C. C., Javaid, M. K., Judge, A., & for the REFReSH Study Group (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2882 · Cited by 70
The crisis of inadequate treatment in osteoporosis
Roux, C., & Briot, K. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30136-5 · Cited by 69
Once‐Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture
Boonen, S., ORWOLL, E. S., Magaziner, J. S., Colon-Emeric, C. S., Adachi, J. D., Bucci-Rechtweg, C. M., Haentjens, P., Kaufman, J., Rizzoli, R., Vanderschueren, D., et al. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03666.x · Cited by 69
Self-citation
Management of Postmenopausal Osteoporosis
Andreopoulou, P., & Bockman, R. S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-070313-022841 · Cited by 72
Zoledronate
Reid, I. R., Green, J. R., Lyles, K. W., Reid, D. M., Trechsel, U., Hosking, D. J., Black, D. M., Cummings, S. R., Russell, R. G. G., & Eriksen, E. F. (2020) · Bone · doi:10.1016/j.bone.2020.115390 · Cited by 68
Self-citation
Is bone quality associated with collagen age?
Leeming, D. J., Henriksen, K., Byrjalsen, I., Qvist, P., Madsen, S. H., Garnero, P., & Karsdal, M. A. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0904-3 · Cited by 71
Zoledronic acid infusion for lumbar interbody fusion in osteoporosis
Tu, C.-W., Huang, K.-F., Hsu, H.-T., Li, H.-Y., Yang, S. S., & Chen, Y. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.05.034 · Cited by 68
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
Lee, S., Glendenning, P., & Inderjeeth, C. A. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1335-x · Cited by 68
Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis
Wolfe, F., Bolster, M. B., O’Connor, C. M., Michaud, K. D., Lyles, K. W., & Colon-Emeric, C. S. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1792 · Cited by 68
Self-citation
Improved Survival of Hip Fracture Patients Treated Within a Comprehensive Geriatric Hip Fracture Unit, Compared With Standard of Care Treatment
Adunsky, A., Lerner‐Geva, L., Blumstein, T., Boyko, V., Mizrahi, E. H., & Arad, M. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.09.003 · Cited by 68
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Fuggle, N. R., Cooper, C. C., Harvey, N. C., Al‐Daghri, N. M., Brandi, M. L., Bruyère, O., Cano, A., Dennison, E. M., Díez‐Pérez, A., Kaufman, J., et al. (2020) · Drugs · doi:10.1007/s40265-020-01364-2 · Cited by 68
Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study
Bondo, L., Eiken, P., & Abrahamsen, B. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2024-8 · Cited by 67
Management Strategy for Symptomatic Bisphosphonate-Associated Incomplete Atypical Femoral Fractures
Saleh, A., Hegde, V. V., Potty, A. G. R., Schneider, R. J., Cornell, C. N., & Lane, J. M. (2012) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-012-9275-y · Cited by 67
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence
Inderjeeth, C. A., Foo, A. C. H., Lai, M. M. Y., & Glendenning, P. (2008) · Bone · doi:10.1016/j.bone.2008.12.003 · Cited by 67
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
Sølling, A. S., Harsløf, T., & Langdahl, B. L. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18775936 · Cited by 67

Authors: Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
Affiliations: Veterans Health Administration (US)
University of Maryland, Baltimore (US)
McMaster University (CA)
Duke Medical Center (US)
Hvidovre Hospital (DK)
Oslo University Hospital (NO)
Savient Pharmaceuticals (United States) (US)
Novartis (Switzerland) (CH)
KU Leuven (BE)
ORCID: Magaziner, Jay S.
Adachi, Jonathan D.
Pieper, Carl F.
Nordsletten, Lars
Zhang, Jie
Mesenbrink, Peter
Eriksen, Erik Fink
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11
Volume: 357
Issue: 18
Pages: 1799-1809
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa074941
PMC: PMC2324066
OpenAlex: W2163830908
Cited by: 2,003
References: 35
Citations by year: 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
FWCI: 160.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
PubMed Central (acceptedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: Amgen
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Sanofi
Savient Pharmaceuticals
Novo Nordisk
Servier
National Institute on Aging (K23AG024787)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Surgery › Hip and Femur Fractures
Keywords: zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks